All Stories

AnaptysBio’s PD-1 drug reduces rheumatoid arthritis in phase 2 trial

AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has hit the goals of a phase 2 rheumatoid arthritis (RA) trial.

Feb 12, 2025 - 16:46
 0
AnaptysBio’s PD-1 drug reduces rheumatoid arthritis in phase 2 trial
AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has hit the goals of a phase 2 rheumatoid arthritis (RA) trial.
Read More

Tags:

Previous Article

Speed Academy: Cheap Car Challenge – 2009 BMW 535i xDrive Touring Wagon

Next Article

Human medicines European public assessment report (EPAR): Skytrofa (previously L...

Related Posts

Merck pens $300M-per-product collab with Epitopea to locate 'hidden' tumor antigens

Merck pens $300M-per-product collab with Epitopea to lo...

Feb 19, 2025  0

Grifols, through pioneering plasma research, looks to reveal early warning signs of Parkinson's

Grifols, through pioneering plasma research, looks to r...

Feb 14, 2025  0

Charles River lays off staffers at Memphis cell therapy manufacturing site

Charles River lays off staffers at Memphis cell therapy...

Feb 19, 2025  0